PMDA Japan Medical Device Registration & Approval

Japan's medical device system separates scientific review from the legal approval decision. The Pharmaceuticals and Medical Devices Agency (PMDA) performs scientific reviews, consultations, inspections, and post-market safety work, while the Ministry of Health, Labour and Welfare (MHLW) makes approval decisions. Some designated devices are certified by Registered Certification Bodies instead of receiving an MHLW approval. PMDA describes these routes in its official medical device review guidance.

Japan classification and authorization routes

Devices are classified as Class I, II, III, or IV according to risk and assigned a Japanese Medical Device Nomenclature (JMDN) code. Class I devices generally follow a notification route. Many designated Class II and some Class III devices can use third-party certification when an applicable certification standard exists. Other Class II and III devices, and Class IV devices, generally require MHLW approval following PMDA review.

The route therefore cannot be selected from class alone. The JMDN code, general or specified control category, certification standard, novelty, intended use, and claims all matter. Foreign classifications and approvals can support the evidence package but do not replace the Japan-specific route analysis.

MAH and DMAH requirements

A product must be placed on the Japanese market through a licensed Marketing Authorization Holder (MAH). Assess a conventional Japanese MAH arrangement versus a designated DMAH structure for an eligible foreign authorization holder; the latter is a specific authorization model, not merely another name for any distributor.

The MAH or DMAH holds significant quality, safety, vigilance, and authority-communication responsibilities. Agreements should cover dossier access, consultation strategy, change control, renewal or maintenance, complaints, adverse-event reporting, recalls, and transfer planning.

Evidence, QMS, and lifecycle

A submission typically includes the intended use and JMDN basis, device description, risk management, verification and validation, clinical evidence where needed, manufacturing-site information, quality-system evidence, and Japanese labeling. QMS conformity is assessed as part of the authorization framework, with scope and inspection needs depending on the product and sites.

PMDA consultation can reduce uncertainty for novel technology, software, clinical evidence, and nonstandard routes. After authorization, the MAH must maintain quality and post-marketing safety systems, evaluate complaints and adverse events, manage recalls and field actions, and assess changes before implementation. Approved scope, sites, labels, and certificates must remain aligned throughout the product lifecycle.

Japan pathway and evidence decisions

The medical-device class does not alone identify every route. Check JMDN, certification standards, claims, novelty and product category. Foreign manufacturing-site registration and QMS conformity are separate from a product notification, certification or approval. See the MAH/DMAH guide before choosing the local ownership model.

Use the official MHLW / PMDA instructions for the filing scope. Maintain a controlled record of the chosen route, current evidence, open gaps, responsible parties and authority responses. Separate fees, document preparation, review and applicant work when planning the launch.

For a multi-country program, use the market directory to coordinate evidence reuse while retaining the local applicant, language, registration and postmarket requirements for each destination.